The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, ...

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games ...

GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...